23.6
TGF-β 신호 전달 경로는 세포 성장, 분화, 부착, 운동성 및 발달을 조절합니다. TGF-β 신호전달을 유도하는 TGF-β 리간드는 잠재 형태로 합성됩니다. 몇몇 프로테아제나 인테그린과 같은 세포 표면 수용체는 잠재 형태에 작용하여 활성 리간드를 방출합니다. 포유류…
형질전환 성장 인자 β 또는 TGF-β 신호 전달 경로는 세포 증식 및 분화를 조절합니다.
이는 TGF-β 수용체 유형 1과 2인 homodimeric serine/threonine kinase receptor에서 시작됩니다.
이합체 단백질인 TGF-β는 II형 TGF-β 수용체와 결합하여 인접한 I형 수용체를 모집하고 인산화하여 활성 사량체 복합체를 형성합니다.
활성화된 TGF-β형 I 수용체는 수용체 활성화 Smad 또는 R-Smad라고 하는 전사 조절자를 모집하고 인산화합니다.
인산화된 R-Smad는 구조적 변화를 겪고 수용체에서 분리됩니다.
두 개의 R-Smads는 인산화되지 않은 co-Smad를 이합체화하고 결합하여 삼중 Smad 복합체를 형성합니다.
Smad 복합체는 핵으로 운반되어 핵 전사 인자와 결합하고 표적 유전자의 전사를 조절합니다.
핵 인산가수분해효소가 R-Smads를 탈인산화하면 복합체가 분해되고 Smads는 세포질로 다시 전위됩니다.
View the full transcript and gain access to JoVE Core videos
Q1: How does TGF-β ligand binding initiate the signaling pathway?
The dimeric TGF-β ligand binds to type II TGF-β receptors, which then recruit and phosphorylate adjacent type I receptors. This phosphorylation activates the type I receptor's serine/threonine kinase domain, forming an active tetrameric receptor complex that propagates the signal downstream through Smad protein phosphorylation.
Q2: What role do R-Smads play in TGF-β signal transduction?
Receptor-activated Smads (R-Smads) such as Smad2 and Smad3 are phosphorylated by activated type I receptors. This phosphorylation unmasks their nuclear localization signal, allowing two R-Smads to dimerize with an unphosphorylated co-Smad like Smad4, forming a trimeric complex that translocates to the nucleus to regulate gene expression.
Q3: How does the Smad complex regulate gene transcription in the nucleus?
The trimeric Smad complex associates with nuclear transcription factors such as TFE3 and binds to gene regulatory sequences in target genes. This binding induces gene expression and elicits appropriate cellular responses. Once the response is complete, nuclear phosphatases dephosphorylate R-Smads, causing complex disassembly and Smad translocation back to the cytosol.
Q4: What are the three mechanisms by which inhibitory Smads downregulate TGF-β signaling?
Inhibitory Smads (I-Smads) such as Smad6 and Smad7 suppress signaling through three pathways: competing with R-Smads for receptor binding to prevent phosphorylation, recruiting Smurfs to ubiquitylate and degrade receptors, and recruiting phosphatases to dephosphorylate receptors. I-Smads also target co-Smad4 for ubiquitylation and degradation.
Q5: How are latent TGF-β ligands activated before pathway initiation?
TGF-β ligands are synthesized in their latent form and require activation before signaling. Proteases or cell surface receptors such as integrins act upon the latent form to release the active ligand. Three mammalian TGF-β isoforms (TGF-β1, TGF-β2, and TGF-β3) bind as homodimers or heterodimers to activate the signaling pathway.
Q6: What is the function of type III TGF-β receptors in ligand presentation?
Type III receptors (RIII) are cell-surface proteoglycans with glycosaminoglycan chains that bind TGF-β ligands first and present them to type II receptors. Alternatively, ligands may directly bind the constitutively active type II receptor. This dual mechanism ensures efficient recruitment and activation of the receptor complex.
Q7: How does TGF-β signaling compare to other kinase receptor pathways?
TGF-β signaling uses serine/threonine kinase receptors and Smad proteins as signal transducers, distinct from receptor tyrosine kinases that activate alternative cascades. While TGF-β regulates cell proliferation and differentiation through Smad-mediated transcription, other signaling pathways like the JAK-STAT signaling pathway employ different receptor types and effector molecules for cellular responses.